Beta-thalassemia: renal complications and mechanisms: a narrative review

Christos Demosthenous(G. Papanikolaou General Hospital), Pantelis Sarafidis(Ippokrateio General Hospital of Thessaloniki), Perla Eleftheriou(University College London), Evangelia Vetsiou(Hippocration General Hospital), Evdokia Mandala(Hippocration General Hospital), Efthymia Vlachaki(Senologic Hellenic Society), Vassilios Perifanis(AHEPA University Hospital), Chrysa Apostolou(Hippocration General Hospital), Aggeliki Kotsiafti(Hippocration General Hospital)
Hematology
January 1, 2019
10.1080/16078454.2019.1599096
Cited by 62

Related Papers

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
|The Lancet|2010|518
The systemic nature of CKD
|Nature Reviews Nephrology|2017|438
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association
|Cardiovascular Research|2023|312
Lipid management in patients with chronic kidney disease
|Nature Reviews Nephrology|2018|275